ProPhase Labs (PRPH) had the highest return in 1996 by a US stock in the Pharmaceuticals Industry, returning 12,378.3%.
| ASSET | YEAR | % RETURN |
|---|---|---|
ProPhase Labs (PRPH) | 1996 | 12,378.3% |
Nektar Therapeutics (NKTR) | 1996 | 51.25% |
AstraZeneca PLC ADR (AZN) | 1996 | 46.73% |
Novo Nordisk A-S (NVO) | 1996 | 37.17% |
Bristol-Myers Squibb (BMY) | 1996 | 37.02% |
Pfizer (PFE) | 1996 | 35.06% |
Eli Lilly and (LLY) | 1996 | 33.25% |
Titan Pharmaceuticals (TTNP) | 1996 | 29.41% |
Merck (MRK) | 1996 | 25.61% |
Johnson & Johnson (JNJ) | 1996 | 18.1% |
GlaxoSmithKline PLC ADR (GSK) | 1996 | 17.92% |
Teva Pharma Industries Ltd ADR (TEVA) | 1996 | 9.76% |
Bausch Health Companies (BHC) | 1996 | -7.38% |
Perrigo (PRGO) | 1996 | -23.16% |
Viatris (VTRS) | 1996 | -27.04% |
Avadel Pharmaceuticals (AVDL) | 1996 | -36.17% |
